Our research is focused on the roles of lipids in biological membranes and the use of lipid nanoparticle (LNP) systems to deliver conventional and genetic drugs. (Read more)
Our interests in LNP systems can be divided into three parts:
Cartoon (not to scale) depicting the various liposomal and lipidic nanoparticle formulations that have reached the clinic. A. Liposome containing hydrophobic drug associated with the bilayer (e.g., Visudyne®). B. ‘Classical’ liposome containing entrapped drug in the interior aqueous space (e.g., AmBisome®, DaunoXome®, Myocet, DepoCyt). C. ‘Classical’ liposome containing a combination of two drugs (e.g., CPX-351, CPX-1). D. Stealth™ (PEGylated) liposome (e.g., Doxil®). E. Lipidic nanoparticle containing entrapped nucleic acids (e.g., Lc-raf-1) F. Solid core lipidic nanoparticle containing siRNA (e.g., ALN-TTR, TKM-ApoB). G. Ligand-targeted PEGylated liposomes (e.g., MM-302). Source: T.M. Allen and P.R. Cullis. Liposomal drug delivery systems: From concept to clinical applications. Advance Drug Delivery Reviews. Volume 65, Issue 1, Pages 1-148 (January 2013).